Kiyoharu Shirakawa

Pharmacological Characterization of FR194921, a New Potent, Selective, and Orally Active Antagonist for Central Adenosine A1 Receptors

Takuya Maemoto, Miho Tada, Takuma Mihara et al. · Journal of Pharmacological Sciences · 2004 · 79 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

The configuration and conformation of the arabinose moiety in platycodins, saponins isolated from , and mi-saponins from based on carbon-13 and hydrogen-1 nmr spectroscopic evidence: The total structures of the saponins

Hiroshi Ishii, Isao Kitagawa, Kazuhiro Matsushita et al. · Tetrahedron Letters · 1981 · 56 citations

Pharmacy, Biochemistry, Chemistry +13

Studies on Cerebral Protective Agents. IX. Synthesis of Novel 1,2,3,4-Tetrahydroisoquinolines as N-Methyl-D-aspartate Antagonists.

Mitsuru Ohkubo, Atsushi Kuno, Kiyotaka Katsuta et al. · Chemical and Pharmaceutical Bulletin · 1996 · 33 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

The Neuroprotective Effect of the Novel Noncompetitive NMDA Antagonist, FR115427 in Focal Cerebral Ischemia in Rats

Kiyotaka Katsuta, Hajime Nakanishi, Kiyoharu Shirakawa et al. · Journal of Cerebral Blood Flow & Metabolism · 1995 · 32 citations

Medicine, Neuroscience, Pharmacology +17

Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine

Miho Tada, Kiyoharu Shirakawa, Nobuya Matsuoka et al. · Psychopharmacology · 2004 · 24 citations

Medicine, Pharmacology, Pharmacotherapy +13